In summary, we present in this study significant evidence that FOLFOX chemotherapy requires CD8 T cells for optimal therapeutic efficacy and maintains CD8 tumor infiltrated lymphocytes in a differentiation stage that is still functional and more amenable to ICB. Here, CD8A is linked to neoplasm.